News
06-09-2008, 06:00 PM
The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) and no Grade 4 (disabling or life-threatening) neuropathy.
More... (http://www.medicalnewstoday.com/articles/109470.php)
More... (http://www.medicalnewstoday.com/articles/109470.php)